The Only Proven Complete Commercialization Expert in the Industry
On average, manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach with less risk and more value.
Over the last three years, EVERSANA has been at the forefront of integrating a comprehensive pharma go-to-market strategy that enables drug manufacturers to launch faster and smarter. Officially referred to as EVERSANA COMPLETE COMMERCIALIZATION®, manufacturers gain full access to launch strategy, execution and long-term outsourced services, including distribution, field support and patient hub services.
EVERSANA COMPLETE COMMERCIALIZATION® is helping pharma companies achieve flexible, agile product launches that meet client and patient needs.
Download Greg Skalicky latest’s article to learn how our complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company.
Author
As President of EVERSANA, Greg is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of executive leadership, Greg understands all facets of…